Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.
Shvartsur A, Bonavida B. · 2015
Read Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. by Shvartsur A, Bonavida B. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4426947.txt.
Introduction
Anna Shvartsur and Benjamin Bonavida reviewed a cell surface protein called Trop2 in Genes and Cancer in 2015. Trop2, made from the Tacstd2 gene, passes calcium signals inside cells and is present in many normal tissues. In many cancers, though, cells make far too much of it, and high levels track with worse outcomes for patients.
Excess Trop2 helps cancer cells renew themselves, grow, invade nearby tissue, and survive, and it has also been tied to drug resistance. The review covers the signals Trop2 sends, the gene switches that control it, and the partners proposed to bind it. It then surveys attacks on Trop2, from antibodies and drug-linked antibodies to small blockers and tiny particles, which slowed tumors in lab and mouse studies.
Catalog record
| CREATOR | Shvartsur A, Bonavida B. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications By Anna Shvartsur, Benjamin Bonavida Published in: Genes & Cancer DOI: 10.18632/genesandcancer.40 ABSTRACT Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. It is an intracellular calcium signal transducer that is differentially expressed in many cancers. It signals cells for self-renewal, proliferation, invasion, and survival. It has stem cell-like qualities. Trop2 is expressed in many normal tissues, though in contrast, it is overexpressed in many cancers and the overexpression of Trop2 is of prognostic significance. Several ligands have been proposed that interact with Trop2. Trop2 signals the cells via different pathways and it is transcriptionally regulated by a complex network of several transcription factors. Trop2 expression in cancer cells has been correlated with drug resistance. Several strategies target Trop2 on cancer cells that include antibodies, antibody fusion proteins, chemical inhibitors, nanoparticles, etc. The in vitro studies and pre-clinical studies, using these various therapeutic treatments, have resulted in significant inhibition of tumor cell growth both in vitro and in vivo in mice. A clinical study is underway using IMMU-132 (hrS7 linked to SN38) in patients with epithelial cancers. This review describes briefly the various characteristics of cancer cells overexpressing Trop2 and the potential application of Trop2 as both a prognostic biomarker and as a therapeutic target to reverse resistance. INTRODUCTION The transmembrane glycoprotein Trop2 is highly expressed in many cancers, but not all, and has differential expression in certain normal tissues. Trop2 is also known as trophoblast antigen 2, cell surface glycoprotein Trop-2/Trop2, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1/GA733, membrane component chromosome 1 surface marker 1 M1S1, epithelial glycoprotein-1, EGP-1, CAA1, Gelatinous Drop-Like Corneal Dystrophy GDLD, and TTD2 [1,2]. It is coded by the gene Tacstd2. It is about 35 kDa [3]. Trop2 spans the cellular membrane: it has an extracellular, a transmembrane, and an intracellular domain, along with a cytoplasmic tail essential for signaling [4]. Trop2 was first discovered in trophoblast cells. Trophoblast cells possess the ability to invade uterine decidua during placental implantation. Lipinski et al, [5] raised monoclonal antibodies against human neoplastic choriocarcinoma trophoblast cell lines via hybridoma technology. This led to the discovery of four new protein antigens (Trop1, 2, 3, and 4) expressed on normal and malignant trophoblast cells. Trop2 was reported to be expressed on syncytio- and cytotrophoblasts [5]. Trop2 may analogously confer the capacity for proliferation and invasion to cancer cells [2,6]. Trop2 is expressed in the cytoplasm when cells become malignant and in some cases of cancer metastasis and recurrence [7]. Trop2 has been implicated in numerous intracellular signaling pathways. Trop2 transduces an intracellular calcium signal. Trop2-induced signal transduction can occur without extracellular Ca2+, suggesting a mobilization of Ca2+ from internal stores. Specific antibodies are used for cross-linking Trop2. This cross-linking leads to a significant rise in cytoplasmic Ca2+ [4]. Trop2 provides crucial signals for cells with requirements for proliferation, survival, self-renewal, and invasion [8]. Trop2 has several ligands, inlcluding claudin-1, claudin-7, cyclin D1, and potentially IGF-1. Trop2 has stem cell-like qualities and regulates cell growth, transformation, regeneration, and proliferation, which explains why its overexpression can lead to tumor progression. It is expressed on the surface of many stem/progenitor cells and has a role in maintaining tight junction integrity [9]. Trop2 might be a modulator and/or an enhancer of EpCAM-induced cell signaling. Trop2 modulation of EpCAM can cause EpCAM to proliferate and migrate into liver parenchyma [4]. Trop2 can foster cell migration without the presence of growth factors. Induced foci formation represents a loss of the ability to maintain cell growth and movement [8]. Regulated Intramembrane Proteolysis (RIP) is required for Trop2 activity; it is necessary for Trop2's enhanced cell growth and self-renewal activity in prostate cancer. RIP cleaves Trop2 through the TNF-α converting enzyme (TACE) followed by γ-secretase cleavage within the transmembrane domain. Cleavage is mediated by presenilin 1 (PS-1), which is the dominant enzyme, and presenilin 2 (PS-2). This cleavage makes two products, namely the extracellular domain (ECD) and the intracellular domain (ICD) [10]. The ECD is shed and found only on the plasma membrane and in the cytoplasm. Secreted ECD causes an increase in sphere size but not in sphere number, which suggests that the ECD increases the proliferation of progenitor cells, specifically of prostate stem cells. Treating prostate cells with secreted ECD leads to the appearance of small 6 kD fragments, suggesting Trop2 cleavage. It is uncertain whether the ECD induces Trop2 cleavage via distinct binding partner interactions or through direct hydrophilic interactions [10]. The ICD is released from the membrane, for the most part, and accumulates in the nucleus. Nuclear ICD is only detected in cancer specimens. Cleavage and activation is required for its transformation activity and it has been associated with human prostate cancer, but it could also be associated with other cancers [10]. The ICD is the functionally dominant part of Trop2. It promotes self-renewal, initiates prostatic intraepithelial neoplasia (PIN) and is involved in a β-catenin-dependent signaling cascade. Figure 1 shows the process of RIP activity and the interaction of the ICD with β-catenin [8]. [Figure: Trop2-Regulated Intramembrane Proteolysis (RIP)RIP is required for Trop2 activity in prostate cancer. Trop2 is cleaved by the TNF-α converting enzyme (TACE), followed by y-secretase. The cleavage is mediated by the enzymes PS-1 and PS-2 in the complex. PS-1 is the dominant enzyme. Two products are made: the extracellular domain (ECD) is shed and is found on the plasma membrane and in the cytoplasm, and the intracellular domain (ICD) is released from the membrane and accumulates in the nucleus (although some is found on the membrane). The ICD is the functionally dominant part of Trop2 in prostate cancer. Within prostate cancer regions, β-catenin colocalizes with the ICD in the nucleus, leading to Trop2 proliferation. This process could possibly occur in other cancers. This colocalization causes upregulation of the downstream targets cyclin D1 and c-myc, which leads to cell growth [10].] The incomplete or aberrant production of Trop2 may cause it to lose its function and to be internalized from the membrane into the cytoplasm, where it plays a role in cancer progression [7]. In GDLD, an accumulation of Trop2 is observed in the Golgi apparatus due to a defective transport [3]. When PIP2 is bound to the cytoplasmic tail of Trop2, phospholipase C (PLC) cleavage is important for Ca2+ release and for Trop2-mediated cell signaling and cell cycle progression [8]. Figure 2 shows this pathway. The exact mechanisms of Trop2 regulation and cell signaling have not been elucidated. [Figure: PLC Cleavage of PIP2 via Trop2 S303 PhosphorylationIf the cytoplasmic tail of Trop2 is bound to PIP2, it might be concentrating Trop2 for hydrolysis by phospholipase C (PLC). Once position S303 on the Trop2's cytoplasmic tail is phosphorylated by protein kinase C (PKC), PIP2 is exposed for cleavage by PLC303 It is uncertain whether S phosphorylation by PKC comes before increased Ca2+ concentration from Trop2 signaling or after or whether this phosphorylation itself releases PIP2 [4]. When PLC cleaves PIP2, this results in an increase of IP3 (inositol 1,4,5-triphosphate) in the cytoplasm and DAG (deacylglycerol) in the plasma membrane. IP3 causes Ca2+ release from the endoplasmic reticulum (ER) [82]. The increase in free Ca2+ and DAG could activate